News >

Precision Medicine Approaches Evolving With CDK4/6, PI3K Inhibitors in HR+ Breast Cancer

Brittany Cote
Published: Friday, Feb 21, 2020

Dr Sara M. Tolaney

Sara M. Tolaney, MD, MPH

The addition of CDK4/6 inhibitors to endocrine therapy in hormone receptor (HR)–positive, HER2-negative breast cancer has significantly improved outcomes for patients, and now the key challenge is determining what sequence to use these agents in, according to Sara Tolaney, MD, MPH.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication